University of Illinois College of Medicine and EpicGenetics Deploy Test to Determine Patients Most Likely to Avoid Potentially Fatal Cytokine Storms that May Trigger the Most Severe Cases of COVID-19

LOS ANGELES & CHICAGO--(BUSINESS WIRE)--Professor Frederick Behm, Head of the University of Illinois College of Medicine at Chicago Department of Pathology, and Dr. Bruce Gillis, CEO of EpicGenetics, announced they have identified a new application for the confirmatory blood test for diagnosing fibromyalgia (FM/a® Test) in an effort to potentially detect those individuals who may be the least at risk for severe and life-threatening cases of COVID-19. The FM/a test is based on findings that fibr

Click to view original post